Clinical Trial Update: Clinical Study of EZH2 Inhibitor Combined With PARP Inhibitor in the Treatment of Patients With Advanced or Recurrent Epithelial Ovarian Cancer. [Phase 2]

View source ↗

Summary

Phase 2 clinical study evaluating the combination of an EZH2 inhibitor with a PARP inhibitor for advanced or platinum-sensitive recurrent epithelial ovarian can…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• EZH2 inhibitor
• PARP inhibitor

Snippet

Sponsor: Peking University Third Hospital | Conditions: Ovariancancer, Platinum-sensitive Recurrent | Phase 2 | Status: NOT_YET_RECRUITING